CYP11A1 and neoplasm: Importantly, in both tumor models, pharmacological inhibition of Cyp11a1 by aminoglutethimide (AG) was sufficient to recapitulate the tumor restriction phenotype resulting from Cyp11a1 genetic ablation (Fig. 5e, f).